ADoTope MC003 / Medicovestor - LARVOL DELTA

MC003: A novel bi-epitope, dual-payload, fixed-combination chemoimmunotherapy antibody drug conjugate for the treatment of folate receptor alpha-expressing ovarian cancer (AACR 2026) - "To enhance therapeutic efficacy and overcome drug resistance, we developed a novel bi-epitope, dual-payload FRα-targeted ADC, designated MC003 (ADoTope FRα ADC), and evaluated its preclinical pharmacology, efficacy, and safety profile. A panel of fully human monoclonal antibodies specific for FRα was isolated from a human v-gene phage display library...In SCID mice bearing established SKOV3 xenografts, MC003 achieved superior tumor growth suppression relative to mirvetuximab soravtansine, a clinically approved FRα ADC... ADoTope enhances FRα targeting by simultaneously engaging two distinct epitopes, effectively functionally increasing the antigen density and enabling the co-delivery of mechanistically distinct cytotoxic payloads. MC003 also mediates efficient ADCC and induces immune activation. These preclinical findings support the advancement of MC003 into IND-enabling studies as the next-generation therapeutic for platinum-resistant ovarian cancer."

ADC • IO biomarker • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD8 • FOLR1 • MMP9

MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting folate receptor alpha in platinum-resistant epithelial ovarian cancer (SITC 2025) - "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development.Ethics Approval All animal experiments were carried out under the Sanyou Biopharmaceuticals Laboratory Animal Ethics Committee.Abstract 995 Figure 1Request permissions"

IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting Folate Receptor Alpha (FRa) in platinum-resistant epithelial ovarian cancer. (AACR-NCI-EORTC 2025) - "While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need in this highly refractory population. Our data provides preclinical support for the ADoTope platform and justifies advancing MC003 to further development for platinum-resistant ovarian cancer treatment. MC003 is currently in IND-enabling stage of development."

IO biomarker • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1